Skip to content

Clinical study for umbilical cord mesenchymal stem cells in the treatment of moderate refractory ulcerative colitis

A randomized control double-blind trial for evaluating the efficacy of umbilical cord mesenchymal stem cells in the treatment of moderate refractory ulcerative colitis

Status
Recruiting
Phases
Phase 2
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026035
Enrollment
Unknown
Registered
2019-09-18
Start date
2018-09-01
Completion date
Unknown
Last updated
2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

Sponsors

He'nan Provincial Peoples Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) male fenale aged 18-65 years old; (2) With refractory ulcerative colitis which meet the diagnostic standard "Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis"; (3) Subjects or their legal representatives are given informed consent, and to be able to complete the full cycle of follow-up.

Exclusion criteria

Exclusion criteria: (1) Mild or severe ulcerative colitis; (2) Patients with known allergies to culture medium; (3) Patients with Crohn's enterocolitis, indeterminate colitis, ischaemic colitis, radiation colitis, drug induced enteritis and colitis of other causes; (4) A history of malignancy or hematological disease; (5) Severe cardiovascular and cerebrovascular diseases: acute cerebrovascular disease or myocardial infarction within 3 months ,uncontrolled high blood pressure (>180/110mmHg) or severe cardiac insufficiency (New York Heart Association IV) or ejection fraction1.5ULN,AST>1.5ULN, SCr>ULN); (8) Pregnant or breastfeeding women; (9) Patients having participated in clinical trials within 3 month prior to enrollment in this study.

Design outcomes

Primary

MeasureTime frame
clinical remission;endoscopic remission;pathological remission;

Countries

China

Contacts

Public ContactBingyong Zhang

He'nan Provincial Peoples Hospital

zhbingyong@sina.com+86 15038197777

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026